Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $225.5 million.

  • Cytokinetics' Cash & Equivalents rose 377.05% to $225.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.5 million, marking a year-over-year increase of 377.05%. This contributed to the annual value of $94.9 million for FY2024, which is 16.35% down from last year.
  • As of Q3 2025, Cytokinetics' Cash & Equivalents stood at $225.5 million, which was up 200.86% from $74.9 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Cash & Equivalents registered a high of $225.5 million during Q3 2025, and its lowest value of $37.2 million during Q2 2021.
  • Its 3-year average for Cash & Equivalents is $110.3 million, with a median of $100.1 million in 2023.
  • The largest annual percentage gain for Cytokinetics' Cash & Equivalents in the last 5 years was 377.05% (2025), contrasted with its biggest fall of 60.66% (2025).
  • Cytokinetics' Cash & Equivalents (Quarterly) stood at $112.7 million in 2021, then slumped by 40.37% to $67.2 million in 2022, then surged by 68.79% to $113.4 million in 2023, then fell by 16.35% to $94.9 million in 2024, then surged by 377.05% to $225.5 million in 2025.
  • Its Cash & Equivalents was $225.5 million in Q3 2025, compared to $74.9 million in Q2 2025 and $73.7 million in Q1 2025.